	Application No.	Applicant(s)
Notice of Allowability	09/994,165	CASTELLI ET AL.
	Examiner	Art Unit
	Konata M. George	1616
The MAILING DATE of this communication and All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOL-8 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.3	IS (OR REMAINS) CLOSED in 35) or other appropriate commu RIGHTS. This application is s	n this application. If not included unication will be mailed in due course. THIS
1. \boxtimes This communication is responsive to <u>RCE filed Decemb</u>	<i>er</i> 29, 2003.	
2. X The allowed claim(s) is/are 14, 15 and 18-21 (renumber	<u>ed 1-6)</u> .	•
3. The drawings filed on are accepted by the Exami	ner.	
 4. Acknowledgment is made of a claim for foreign priority a) All b) Some* c) None of the: 1. Certified copies of the priority documents hat 2. Certified copies of the priority documents hat 3. Copies of the certified copies of the priority International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	ave been received. ave been received in Applicatio	on No
Applicant has THREE MONTHS FROM THE "MAILING DATI noted below. Failure to timely comply will result in ABANDOI THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	NMENT of this application.	
 A SUBSTITUTE OATH OR DECLARATION must be substituted in the substitution (PTO-152) which g 		
6. CORRECTED DRAWINGS (as "replacement sheets") m	nust be submitted.	•
(a) ☐ including changes required by the Notice of Draftspo	-	v (PTO-948) attached
1) ☐ hereto or 2) ☐ to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examine Paper No./Mail Date	er's Amendment / Comment or	in the Office action of
Identifying indicia such as the application number (see 37 CFF each sheet. Replacement sheet(s) should be labeled as such i	R 1.84(c)) should be written on the the header according to 37 CF	ne drawings in the front (not the back) of R 1.121(d).
 DEPOSIT OF and/or INFORMATION about the department of the department of		
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Inf	formal Patent Application (PTO-152)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948		ummary (PTO-413), Mail Date
 Information Disclosure Statements (PTO-1449 or PTO/SE Paper No./Mail Date 	B/08), 7. Examiner's	Amendment/Comment
Examiner's Comment Regarding Requirement for Deposi of Biological Material	t 8. ⊠ Examiner's 9. □ Other	Statement of Reasons for Allowance

Application/Control Number: 09/994,165

Art Unit: 1616

DETAILED ACTION

Claims 14, 15 and 18-21 are pending in this application.

Information Disclosure Statement

1. The information disclosure statement (IDS) submitted on December 29, 2003 and October 27, 2004 was noted and the submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the examiner has considered the information disclosure statement.

Request for Continued Examination (RCE)

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on December 29, 2003 has been entered.

Application/Control Number: 09/994,165 Page 3

Art Unit: 1616

Statement of Reasons for Allowance

3. The following is an examiner's statement of reasons for allowance:

The claims are allowable over the cited prior art because the prior art does not teach, disclose nor make obvious the composition having hypoallergenic or immunomodulatory activity for the treatment of sensitive skin made according to the claimed process. The closet prior art of Murad (US 5,804,168) discloses compositions comprising at least one anti-oxidant component and at least one anti-inflammatory component. The prior art does not teach by combining the two active agents one of the activities, one of the activities is potentiated by the combination of these two components. The closet prior art does not teach a composition comprising a Ginkgo biloba extract and β -glucan together with components that exhibit at least on activity selected from anti-inflammatory, anti-radical and/or anti-allergic or at least two components having two different activities.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

4. Claims 14, 15 and 18-21 are allowed.

Page 4

Application/Control Number: 09/994,165

Art Unit: 1616

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is (571) 272-0613. The examiner can normally be reached from 8AM to 6:30PM Monday to Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached at (571) 272-0887. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Konata M. George

SHELLEY A. DODSON PRIMARY EXAMINER